We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+37.89%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$3.91B
AUM Growth
+$772M
Cap. Flow
-$38.9M
Cap. Flow %
-0.99%
Top 10 Hldgs %
65.59%
Holding
46
New
5
Increased
6
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
XOMA
Xoma
XOMA
+$203M
2
QTTB icon
Q32 Bio
QTTB
+$19.6M
3
SGMT icon
Sagimet Biosciences
SGMT
+$17M
4
RVMD icon
Revolution Medicines
RVMD
+$15.8M
5
ABSI icon
Absci
ABSI
+$13.3M

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$140M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$53.1M
3
CMPX icon
Compass Therapeutics
CMPX
+$41.1M
4
PVLA
Palvella Therapeutics
PVLA
+$35M
5
SEPN
Septerna Inc
SEPN
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.14%
3 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$555M 14.2%
2,965,160
+108,378
+4% +$15.8M
KYMR icon
2
Kymera Therapeutics
KYMR
$9.82B
$444M 11.35%
3,872,052
-1,630,658
-30% -$140M
XOMA
3
DELISTED
Xoma
XOMA
$323M 8.25%
7,593,303
+5,003,000
+193% +$203M
MLTX icon
4
MoonLake Immunotherapeutics
MLTX
$1.28B
$312M 7.97%
16,001,284
– –
GHRS icon
5
GH Research
GHRS
$1.92B
$233M 5.95%
8,650,158
– –
GPCR icon
6
Structure Therapeutics
GPCR
$3.38B
$181M 4.62%
3,366,823
-92,535
-3% -$4.09M
NKTR icon
7
Nektar Therapeutics
NKTR
$2.48B
$167M 4.27%
2,391,075
-168,520
-7% -$12.3M
MIRM icon
8
Mirum Pharmaceuticals
MIRM
$5.94B
$124M 3.16%
1,056,027
-528,700
-33% -$53.1M
XNCR icon
9
Xencor
XNCR
$1.94B
$115M 2.94%
7,133,720
– –
ALKS icon
10
Alkermes
ALKS
$7.95B
$113M 2.89%
2,154,704
+154,704
+8% +$6.04M
GLUE icon
11
Monte Rosa Therapeutics
GLUE
$1.14B
$108M 2.76%
4,460,886
– –
CGEM icon
12
Cullinan Oncology
CGEM
$1.4B
$105M 2.68%
5,750,683
– –
PVLA
13
Palvella Therapeutics
PVLA
$2.16B
$103M 2.63%
672,789
-288,200
-30% -$35M
ZYME icon
14
Zymeworks
ZYME
$2.02B
$95.4M 2.44%
3,649,142
-85,000
-2% -$2.16M
KURA icon
15
Kura Oncology
KURA
$1.13B
$92.7M 2.37%
8,445,769
– –
IRON icon
16
Disc Medicine
IRON
$3.07B
$84.4M 2.16%
1,153,612
-118,700
-9% -$8.16M
STOK icon
17
Stoke Therapeutics
STOK
$2.04B
$83.4M 2.13%
2,547,557
– –
OLMA icon
18
Olema Pharmaceuticals
OLMA
$899M
$66.3M 1.69%
5,295,893
– –
ANNX icon
19
Annexon
ANNX
$942M
$49.7M 1.27%
8,698,173
– –
CBIO
20
Crescent Biopharma
CBIO
$659M
$49.5M 1.27%
2,748,763
– –
ACIU icon
21
AC Immune
ACIU
$263M
$47.2M 1.21%
19,822,436
– –
TYRA icon
22
Tyra Biosciences
TYRA
$1.49B
$47.1M 1.21%
1,476,196
-500,000
-25% -$16.5M
STRO icon
23
Sutro Biopharma
STRO
$339M
$41.6M 1.06%
1,251,788
– –
IMCR icon
24
Immunocore
IMCR
$1.89B
$41.1M 1.05%
1,294,463
– –
AVTX icon
25
Avalo Therapeutics
AVTX
$1.05B
$38.4M 0.98%
2,075,545
+442,700
+27% +$7M
1
2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q2 2026 Portfolio in Review

As of Q2 2026, BVF Inc held 46 positions worth $3.91B, up 25% from $3.14B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

BVF Inc's Q2 2026 filing shows 5 new, 6 increased, 9 reduced and 2 closed positions. Its largest new stake was Q32 Bio: 2,350,000 shares worth $29.9M. The largest sale was Kymera Therapeutics, an estimated $140M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • BVF Inc's largest Q2 2026 buy was Q32 Bio: 2,350,000 shares worth $29.9M.
  • BVF Inc added most to Xoma in Q2 2026, an estimated $203M increase.
  • BVF Inc's biggest Q2 2026 reduction was Kymera Therapeutics, cutting an estimated $140M.
  • BVF Inc fully exited Compass Therapeutics in Q2 2026, selling an estimated $41.1M.
  • BVF Inc's ten largest holdings make up 66% of its $3.91B portfolio in Q2 2026.
  • BVF Inc opened 5 new positions and closed 2 in Q2 2026.
  • BVF Inc's portfolio value rose 25% quarter-over-quarter to $3.91B.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.